Table 2.
Association of incompatibility at G1m (G1m1,17- genotype) with less improvement in DAS28 at six months of treatment with anti-TNF in the discovery samples
| Unadjusted | Adjusted b | Adjusted b | ||||||
|---|---|---|---|---|---|---|---|---|
| G1m genotype a | number | Baseline DAS28 | ΔDAS28 | Beta | P-value | Beta | P-value | |
| All patients | G1m1,17+ | 92 | 5.9 ± 1.1 | 2.3 ± 1.6 | 0.20 | 0.006 | 0.14 | 0.02 |
| G1m1,17- | 94 | 5.7 ± 1.1 | 1.6 ± 1.5 | |||||
| INX | G1m1,17+ | 68 | 5.9 ± 1.1 | 2.1 ± 1.6 | 0.16 | 0.06 | 0.16 | 0.03 |
| G1m1,17- | 72 | 5.8 ± 1.1 | 1.6 ± 1.5 | |||||
| ADM | G1m1,17+ | 24 | 6.1 ± 1.3 | 2.9 ± 1.5 | 0.32 | 0.03 | 0.16 | 0.19 |
| G1m1,17- | 22 | 5.6 ± 1.4 | 1.9 ± 1.5 | |||||
aCarrier status; banalyses adjusted for baseline DAS28, gender and RF (and anti-TNF for All patients). ADM, adalimumab; anti-TNF, anti-tumor necrosis factor; DAS28, disease activity score in 28 joints; INX, infliximab; RF, rheumatoid factor.